Search

Your search keyword '"Julio Andrea"' showing total 8 results
Start Over Author "Julio Andrea" Topic endocarditis
8 results on '"Julio Andrea"'

1. Infective Endocarditis Caused by Staphylococcus Aureus after Transcatheter Aortic Valve Replacement

Author

Fernando Alfonso, Marco Barbanti, Oliver Husser, Harindra C. Wijeysundera, Jean-Bernard Masson, Ignacio J. Amat-Santos, Samir R. Kapadia, Marina Urena, Francisco Campelo-Parada, Vinicius Esteves, Roger R. Godinho, Tarun Chakravarty, Marcos Antonio Marino, Stamatios Lerakis, Alexandre Siciliano Colafranceschi, Marouane Boukhris, Chekrallah Chamandi, Lisa Crusius, Tomasz Gasior, Azeem Latib, Norman Mangner, Utz Kappert, Josep Rodés-Cabau, José Armando Mangione, Francesco Rosato, Axel Linke, Sandro Sponga, Erika Muñoz-García, Valter Corriea de Lima, Susheel Kodali, Asim N. Cheema, Lars Søndergaard, Igor Vendramin, Alexandre Abizaid, Antonio L. Bartorelli, Annapoorna Kini, Rosana Hernández-Antolín, John G. Webb, Costanza Pellegrini, Didier Tchetche, Howard C. Herrmann, John Lisko, Claudia Fiorina, Mohamed Abdel-Wahab, Kim Won-Keun, Hélène Eltchaninoff, Alberto Alperi, Martin Landt, Dominique Himbert, Frédéric Maes, Victoria Vilalta, Luca Testa, Isaac Pascual, Luisa Salido, Jan Malte Sinning, Vicenç Serra, Guglielmo Mario Actis Dato, Antonio Miceli, Clement Servoz, David del Val, Rafael Romaguera, Maria-Cristina Ferreira, Eric Durand, Julio Andrea, Fabio Sandoli de Brito, Vincent Auffret, Philippe Gervais, Stefan Stortecky, Paolo Olivares, Francesco Giannini, Enrique Gutiérrez-Ibañes, Raj Makkar, Nikolaj Ihlemann, Wojtek Wojakowski, Hervé Le Breton, Abdullah Alkhodair, Juan C. Castillo, Ander Regueiro, David Holzhey, Luis Nombela-Franco, Henrique Barbosa Ribeiro, Saif Siddiqui, Université Laval [Québec] (ULaval), Universität Leipzig [Leipzig], Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Toulouse [Toulouse], Clinique Pasteur, Clinique Pasteur [Toulouse], Mount Sinai Hospital [Toronto, Canada] (MSH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), University Hospital Leipzig, Edwards Lifesciences, Fundación Alfonso Martín Escudero, Abbott Laboratories, Medtronic, Boston Scientific Corporation, UCL - (SLuc) Département cardiovasculaire, UCL - SSS/IREC/SLUC - Pôle St.-Luc, Hôpital de Rangueil, Universität Leipzig, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
Male, medicine.medical_specialty, Staphylococcus aureus, Prosthesis-Related Infections, Transcatheter aortic, medicine.medical_treatment, [SDV]Life Sciences [q-bio], 030204 cardiovascular system & hematology, medicine.disease_cause, Global Health, Prosthesis, Sepsis, Transcatheter Aortic Valve Replacement, 03 medical and health sciences, 0302 clinical medicine, Valve replacement, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Risk Factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, medicine, Endocarditis, Humans, 030212 general & internal medicine, Hospital Mortality, Registries, 610 Medicine & health, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Incidence, Aortic Valve Stenosis, Endocarditis, Bacterial, Staphylococcal Infections, medicine.disease, 3. Good health, Surgery, Survival Rate, Infective endocarditis, Aortic Valve, Heart Valve Prosthesis, Etiology, Female, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies
Abstract

International audience; Background - Staphylococcus aureus (SA) has been extensively studied as causative microorganism of surgical prosthetic-valve infective endocarditis (IE). However, scarce evidence exists on SA IE after transcatheter aortic valve replacement (TAVR). Methods - Data were obtained from the Infectious Endocarditis After TAVR International Registry, including patients with definite IE after TAVR from 59 centres in 11 countries. Patients were divided into 2 groups according to microbiologic etiology: non-SA IE vs SA IE. Results - SA IE was identified in 141 patients out of 573 (24.6%), methicillin-sensitive SA in most cases (115/141, 81.6%). Self-expanding valves were more common than balloon-expandable valves in patients presenting with early SA IE. Major bleeding and sepsis complicating TAVR, neurologic symptoms or systemic embolism at admission, and IE with cardiac device involvement (other than the TAVR prosthesis) were associated with SA IE (P < 0.05 for all). Among patients with IE after TAVR, the likelihood of SA IE increased from 19% in the absence of those risk factors to 84.6% if ≥ 3 risk factors were present. In-hospital (47.8% vs 26.9%; P < 0.001) and 2-year (71.5% vs 49.6%; P < 0.001) mortality rates were higher among patients with SA IE vs non-SA IE. Surgery at the time of index SA IE episode was associated with lower mortality at follow-up compared with medical therapy alone (adjusted hazard ratio 0.46, 95% CI 0.22-0.96; P = 0.038). Conclusions - SA IE represented approximately 25% of IE cases after TAVR and was associated with very high in-hospital and late mortality. The presence of some features determined a higher likelihood of SA IE and could help to orientate early antibiotic regimen selection. Surgery at index SA IE was associated with improved outcomes, and its role should be evaluated in future studies.

Published
2022
Full Text
View/download PDF

2. Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation

Author

Vassili Panagides, David del Val, Mohamed Abdel-Wahab, Norman Mangner, Eric Durand, Nikolaj Ihlemann, Marina Urena, Costanza Pellegrini, Francesco Giannini, Piotr Scislo, Zenon Huczek, Martin Landt, Vincent Auffret, Jan Malte Sinning, Asim N. Cheema, Luis Nombela-Franco, Chekrallah Chamandi, Francisco Campelo-Parada, Erika Munoz-Garcia, Howard C Herrmann, Luca Testa, Won-Keun Kim, Juan Carlos Castillo, Alberto Alperi, Didier Tchetche, Antonio L. Bartorelli, Samir Kapadia, Stefan Stortecky, Ignacio Amat-Santos, Harindra C. Wijeysundera, John Lisko, Enrique Gutiérrez-Ibanes, Vicenç Serra, Luisa Salido, Abdullah Alkhodair, Ugolino Livi, Tarun Chakravarty, Stamatios Lerakis, Victoria Vilalta, Ander Regueiro, Rafael Romaguera, Utz Kappert, Marco Barbanti, Jean-Bernard Masson, Frédéric Maes, Claudia Fiorina, Antonio Miceli, Susheel Kodali, Henrique B. Ribeiro, Jose Armando Mangione, Fabio Sandoli de Brito, Guglielmo Mario Actis Dato, Francesco Rosato, Maria-Cristina Ferreira, Valter Correia de Lima, Alexandre Siciliano Colafranceschi, Alexandre Abizaid, Marcos Antonio Marino, Vinicius Esteves, Julio Andrea, Roger R. Godinho, Fernando Alfonso, Helene Eltchaninoff, Lars Søndergaard, Dominique Himbert, Oliver Husser, Azeem Latib, Hervé Le Breton, Clement Servoz, Isaac Pascual, Saif Siddiqui, Paolo Olivares, Rosana Hernandez-Antolin, John G. Webb, Sandro Sponga, Raj Makkar, Annapoorna S. Kini, Marouane Boukhris, Philippe Gervais, Axel Linke, Lisa Crusius, David Holzhey, Josep Rodés-Cabau, Université Laval [Québec] (ULaval), Universität Leipzig [Leipzig], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Rigshospitalet [Copenhagen], Copenhagen University Hospital, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Deutsches Herzzentrum München (DHM), Ospedale San Raffaele, Medical University of Warsaw - Poland, Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital Rangueil, CHU Toulouse [Toulouse], UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Département cardiovasculaire, Universität Leipzig, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
MESH: Endocarditis, Catheters, MESH: Humans, Endocarditis, MESH: Heart Valve Prosthesis, Aortic Valve Insufficiency, Aortic Valve Stenosis, MESH: Aortic Valve Insufficiency, MESH: Mitral Valve, Transcatheter Aortic Valve Replacement, Treatment Outcome, Risk Factors, MESH: Risk Factors, Aortic Valve, Heart Valve Prosthesis, Humans, Mitral Valve, [SDV.IB]Life Sciences [q-bio]/Bioengineering, MESH: Transcatheter Aortic Valve Replacement, MESH: Catheters, Cardiology and Cardiovascular Medicine, 610 Medicine & health, MESH: Aortic Valve, MESH: Aortic Valve Stenosis, MESH: Treatment Outcome
Abstract

Scarce data exist on mitral valve (MV) infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). This multicenter study included a total of 579 patients with a diagnosis of definite IE after TAVI from the IE after TAVI International Registry and aimed to evaluate the incidence, characteristics, management, and outcomes of MV-IE after TAVI. A total of 86 patients (14.9%) had MV-IE. These patients were compared with 284 patients (49.1%) with involvement of the transcatheter heart valve (THV) only. Two factors were found to be associated with MV-IE: the use of self-expanding valves (adjusted odds ratio 2.49, 95% confidence interval [CI] 1.23 to 5.07, p = 0.012), and the presence of an aortic regurgitation >= 2 at discharge (adjusted odds ratio 3.33; 95% CI 1.43 to 7.73, p < 0.01). There were no differences in IE timing and causative microorganisms between groups, but surgical management was significantly lower in patients with MV-IE (6.0%, vs 21.6% in patients with THV-IE, p = 0.001). All-cause mortality rates at 2-year follow-up were high and similar between patients with MV-IE (51.4%, 95% CI 39.8 to 64.1) and patients with THV-IE (51.5%, 95% CI 45.4 to 58.0) (log-rank p = 0.295). The factors independently associated with increased mortality risk in patients with MV-IE were the occurrence of heart failure (adjusted p < 0.001) and septic shock (adjusted p < 0.01) during the index hospitalization. One of 6 IE episodes after TAVI is localized on the MV. The implantation of a self-expanding THV and the presence of an aortic regurgitation >= 2 at discharge were associated with MV-IE. Patients with MV-IE were rarely operated on and had a poor prognosis at 2-year follow-up. (C) 2022 Elsevier Inc. All rights reserved.

Published
2022
Full Text
View/download PDF

3. Perivalvular Extension of Infective Endocarditis after Transcatheter Aortic Valve Replacement

Author

Vassili Panagides, David del Val, Mohamed Abdel-Wahab, Norman Mangner, Eric Durand, Nikolaj Ihlemann, Marina Urena, Costanza Pellegrini, Francesco Giannini, Tomasz Gasior, Wojtek Wojakowski, Martin Landt, Vincent Auffret, Jan Malte Sinning, Asim N Cheema, Luis Nombela-Franco, Chekrallah Chamandi, Francisco Campelo-Parada, Erika Munoz-Garcia, Howard C Herrmann, Luca Testa, Won Keun Kim, Juan Carlos Castillo, Alberto Alperi, Didier Tchetche, Antonio L Bartorelli, Samir Kapadia, Stefan Stortecky, Ignacio Amat-Santos, Harindra C Wijeysundera, John Lisko, Enrique Gutiérrez-Ibanes, Vicenç Serra, Luisa Salido, Abdullah Alkhodair, Ugolino Livi, Tarun Chakravarty, Stamatios Lerakis, Victoria Vilalta, Ander Regueiro, Rafael Romaguera, Utz Kappert, Marco Barbanti, Jean Bernard Masson, Frédéric Maes, Claudia Fiorina, Antonio Miceli, Susheel Kodali, Henrique B Ribeiro, Jose Armando Mangione, Fabio Sandoli de Brito, Guglielmo Mario Actis Dato, Francesco Rosato, Maria Cristina Ferreira, Valter Correia de Lima, Alexandre Siciliano Colafranceschi, Alexandre Abizaid, Marcos Antonio Marino, Vinicius Esteves, Julio Andrea, Roger R Godinho, Fernando Alfonso, Helene Eltchaninoff, Lars Søndergaard, Dominique Himbert, Oliver Husser, Azeem Latib, Hervé Le Breton, Clement Servoz, Isaac Pascual, Saif Siddiqui, Paolo Olivares, Rosana Hernandez-Antolin, John G Webb, Sandro Sponga, Raj Makkar, Annapoorna S Kini, Marouane Boukhris, Philippe Gervais, Axel Linke, Lisa Crusius, David Holzhey, Josep Rodés-Cabau, Université Laval [Québec] (ULaval), Universität Leipzig, Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Clinique Pasteur [Toulouse], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Leipzig University, Universität Leipzig [Leipzig], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Hôpital de Rangueil, CHU Toulouse [Toulouse], Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Microbiology (medical), Coagulase, Infective endocarditis, TAVI, TAVR, heart surgery, Endocarditis, infective endocarditis, 610 Medicine & health, Endocarditis, Bacterial, 030204 cardiovascular system & hematology, Abscess, 3. Good health, Transcatheter Aortic Valve Replacement, 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, Risk Factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Humans, 030212 general & internal medicine, Renal Insufficiency, Chronic, Aneurysm, False
Abstract

Background Infective endocarditis (IE) following transcatheter aortic valve replacement (TAVR) has been associated with a dismal prognosis. However, scarce data exist on IE perivalvular extension (PEE) in such patients. Methods This multicenter study included 579 patients who had the diagnosis of definite IE at a median of 171 (53–421) days following TAVR. PEE was defined as the presence of an intracardiac abscess, pseudoaneurysm, or fistula. Results A total of 105 patients (18.1%) were diagnosed with PEE (perivalvular abscess, pseudoaneurysm, fistula, or a combination in 87, 7, 7, and 4 patients, respectively). A history of chronic kidney disease (adjusted odds ratio [ORadj], 2.08; 95% confidence interval [CI]: 1.27–3.41; P = .003) and IE secondary to coagulase-negative staphylococci (ORadj, 2.71; 95% CI: 1.57–4.69; P Conclusions PEE occurred in about one-fifth of IE post-TAVR patients, with the presence of coagulase-negative staphylococci and chronic kidney disease determining an increased risk. Patients with PEE-IE exhibited high early and late mortality rates, and surgery during IE hospitalization seemed to be associated with better outcomes.

Published
2021
Full Text
View/download PDF

4. Stroke Complicating Infective Endocarditis After Transcatheter Aortic Valve Replacement

Author

Fernando Alfonso, Marco Barbanti, Alexandre Abizaid, Howard C. Herrmann, John Lisko, Luis Nombela-Franco, Eric Durand, Julio Andrea, Sandro Sponga, Oliver Husser, Vincent Auffret, Ander Regueiro, Susheel Kodali, Victoria Vilalta, Marcos Antonio Marino, Marouane Boukhris, Asim N. Cheema, Saif Siddiqui, Isaac Pascual, David Holzhey, Paolo Olivares, Josep Rodés-Cabau, Maria Cristina Ferreira, Hervé Le Breton, Norman Mangner, Vinicius Esteves, Tarun Chakravarty, Vicenç Serra, Martin Landt, Guglielmo Mario Actis Dato, Abdullah Alkhodair, Francesco Giannini, Dominique Himbert, Tomasz Gasior, Wojtek Wojakowski, Valter C. Lima, Azeem Latib, Utz Kappert, Antonio L. Bartorelli, Annapoorna Kini, Enrique Gutiérrez-Ibañes, Juan C. Castillo, Mohamed Abdel-Wahab, Erika Muñoz-García, José Armando Mangione, Clement Servoz, Ignacio J. Amat-Santos, Francisco Campelo-Parada, Stefan Stortecky, Francesco Rosato, Luca Testa, Marina Urena, Luisa Salido, Ugolino Livi, Alexandre Siciliano Colafranceschi, Chekrallah Chamandi, Lisa Crusius, Samir R. Kapadia, Harindra C. Wijeysundera, Roger R. Godinho, Stamatios Lerakis, Frédéric Maes, Jean Bernard Masson, Rosana Hernández-Antolín, Didier Tchetche, Antonio Miceli, Fabio Sandoli de Brito, David del Val, Axel Linke, Lars Søndergaard, Costanza Pellegrini, Alberto Alperi, Jan Malte Sinning, John G. Webb, Claudia Fiorina, Kim Won-Keun, Hélène Eltchaninoff, Henrique Barbosa Ribeiro, Nikolaj Ihlemann, Rafael Romaguera, Philippe Gervais, Raj Makkar, Université Laval [Québec] (ULaval), Universität Leipzig [Leipzig], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pontchaillou [Rennes], Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital de Rangueil, CHU Toulouse [Toulouse], Clinique Pasteur [Toulouse], Universität Leipzig, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
Male, medicine.medical_specialty, infective endocarditis, prosthetic valve endocarditis, stroke, TAVR, transcatheter aortic valve implantation, medicine.medical_treatment, 030204 cardiovascular system & hematology, Transcatheter Aortic Valve Replacement, 03 medical and health sciences, Postoperative Complications, 0302 clinical medicine, Valve replacement, Risk Factors, Internal medicine, medicine, Humans, Endocarditis, 030212 general & internal medicine, Embolization, 610 Medicine & health, Stroke, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Incidence, Mortality rate, Incidence (epidemiology), Endocarditis, Bacterial, medicine.disease, 3. Good health, Infective endocarditis, Bacteremia, Cardiology, Female, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Cardiology and Cardiovascular Medicine, business
Abstract

BACKGROUND Stroke is one of the most common and potentially disabling complications of infective endocarditis (IE). However, scarce data exist about stroke complicating IE after transcatheter aortic valve replacement (TAVR). OBJECTIVES The purpose of this study was to determine the incidence, risk factors, clinical characteristics, management, and outcomes of patients with definite IE after TAVR complicated by stroke during index IE hospitalization. METHODS Data from the Infectious Endocarditis after TAVR International Registry (including 569 patients who developed definite IE following TAVR from 59 centers in 11 countries) was analyzed. Patients were divided into two groups according to stroke occurrence during IE admission (stroke [S-IE] vs. no stroke [NS-IE]). RESULTS A total of 57 (10%) patients had a stroke during IE hospitalization, with no differences in causative microorganism between groups. S-IE patients exhibited higher rates of acute renal failure, systemic embolization, and persistent bacteremia (p < 0.05 for all). Previous stroke before IE, residual aortic regurgitation >= moderate after TAVR, balloon-expandable valves, IE within 30 days after TAVR, and vegetation size >8 mm were associated with a higher risk of stroke during the index IE hospitalization (p < 0.05 for all). Stroke rate in patients with no risk factors was 3.1% and increased up to 60% in the presence of >3 risk factors. S-IE patients had higher rates of in-hospital mortality (54.4% vs. 28.7%; p < 0.001) and overall mortality at 1 year (66.3% vs. 45.6%; p < 0.001). Surgical treatment was not associated with improved outcomes in S-IE patients (in-hospital mortality: 46.2% in surgical vs. 58.1% in no surgical treatment; p = 0.47). CONCLUSIONS Stroke occurred in 1 of 10 patients with IE post-TAVR. A history of stroke, short time between TAVR and IE, vegetation size, valve prosthesis type, and residual aortic regurgitation determined an increased risk. The occurrence of stroke was associated with increased in-hospital and 1-year mortality rates, and surgical treatment failed to improve clinical outcomes. (C) 2021 by the American College of Cardiology Foundation.

Published
2021
Full Text
View/download PDF

5. Temporal Trends, Characteristics, and Outcomes of Infective Endocarditis After Transcatheter Aortic Valve Replacement

Author

Rosana Hernández-Antolín, Didier Tchetche, Dominique Himbert, Rafael Romaguera, Ander Regueiro, Alexandre Abizaid, Clement Servoz, Maria-Cristina Ferreira, Martin Landt, Axel Linke, Vincent Auffret, Marco Barbanti, Raj Makkar, Marcos Antonio Marino, David Holzhey, Nikolaj Ihlemann, Valter Correa Lima, Vicenç Serra, Guglielmo Mario Actis Dato, Ignacio J. Amat-Santos, Josep Rodés-Cabau, Frédéric Maes, Francisco Campelo-Parada, Julio Andrea, Stamatios Lerakis, Paolo Olivares, Marouane Boukhris, Henrique Barbosa Ribeiro, Fabio Sandoli de Brito, Azeem Latib, Francesco Giannini, Asim N. Cheema, José Armando Mangione, Susheel Kodali, Enrique Gutiérrez-Ibañes, Marina Urena, Luca Testa, Vinicius Esteves, Luisa Salido, Ugolino Livi, Saif Siddiqui, Samir R. Kapadia, John G. Webb, Lars Søndergaard, Alexandre Siciliano Colafranceschi, Claudia Fiorina, Chekrallah Chamandi, Kim Won-Keun, Hélène Eltchaninoff, Oliver Husser, Isaac Pascual, Lisa Crusius, Costanza Pellegrini, Alberto Alperi, Jan Malte Sinning, David del Val, Hervé Le Breton, Abdullah Alkhodair, Howard C. Herrmann, John Lisko, Juan C. Castillo, Antonio J. Muñoz-García, Norman Mangner, Eric Durand, Antonio L. Bartorelli, Luis Nombela-Franco, Antonio Miceli, Annapoorna Kini, Mohamed Abdel-Wahab, Harindra C. Wijeysundera, Jean-Bernard Masson, Roger R. Godinho, Francesco Rosato, Victoria Vilalta, Stefan Stortecky, Sandro Sponga, Tarun Chakravarty, UCL - SSS/IREC/SLUC - Pôle St.-Luc, and UCL - (SLuc) Département cardiovasculaire

Subjects
Microbiology (medical), medicine.medical_specialty, medicine.medical_treatment, Settore MED/11 - Malattie dell'Apparato Cardiovascolare, 030204 cardiovascular system & hematology, TAVR, Transcatheter Aortic Valve Replacement, 03 medical and health sciences, 0302 clinical medicine, Postoperative Complications, Valve replacement, infective endocarditis, prosthetic valve endocarditis, transcatheter aortic valve replacement, Risk Factors, Internal medicine, Medicine, Humans, 030212 general & internal medicine, 610 Medicine & health, Stroke, Endocarditis, business.industry, Incidence (epidemiology), Mortality rate, Incidence, Acute kidney injury, Endocarditis, Bacterial, medicine.disease, Infectious Diseases, Treatment Outcome, Infective endocarditis, Heart failure, Cohort, Cardiology, business
Abstract

BackgroundProcedural improvements combined with the contemporary clinical profile of patients undergoing transcatheter aortic valve replacement (TAVR) may have influenced the incidence and outcomes of infective endocarditis (IE) following TAVR. We aimed to determine the temporal trends, characteristics, and outcomes of IE post-TAVR.MethodsObservational study including 552 patients presenting definite IE post-TAVR. Patients were divided in 2 groups according to the timing of TAVR (historical cohort [HC]: before 2014; contemporary cohort [CC]: after 2014).ResultsOverall incidence rates of IE were similar in both cohorts (CC vs HC: 5.45 vs 6.52 per 1000 person-years; P = .12), but the rate of early IE was lower in the CC (2.29‰ vs 4.89‰, P ConclusionsAlthough overall IE incidence has remained stable, the incidence of early IE has declined in recent years. The microorganism, high rate of complications, and very low rate of surgical treatment remained similar. In-hospital and 1-year mortality rates were high but progressively decreased over time.

Published
2021
Full Text
View/download PDF

6. Long-Term Outcomes After Infective Endocarditis After Transcatheter Aortic Valve Replacement

Author

Asim N. Cheema, Lars Søndergaard, Tarun Chakravarty, Ignacio J. Amat-Santos, Josep Rodés-Cabau, Antonio J. Muñoz-García, Norman Mangner, Vincent Auffret, Costanza Pellegrini, Enrique Gutiérrez-Ibanez, Jan Malte Sinning, Didier Tchetche, Luca Testa, Dominique Himbert, Francesco Rosato, David del Val, Antonio L. Bartorelli, John G. Webb, Luis Nombela-Franco, Antonio Miceli, Alexandre Abizaid, Claudia Fiorina, Hervé Le Breton, Azeem Latib, Kim Won-Keun, Marcos Antonio Marino, Hélène Eltchaninoff, Marco Barbanti, Vinicius Esteves, José Armando Mangione, Howard C. Herrmann, John Lisko, Abdullah Alkhodair, Fabio Sandoli de Brito, Vicenç Serra, Guglielmo Mario Actis Dato, Martin Landt, Harindra C. Wijeysundera, Juan C. Castillo, Eric Durand, Stamatios Lerakis, Axel Linke, Marina Urena, Paolo Olivares, Maria Cristina Ferreira, Ugolino Livi, Jean Bernard Masson, Mohamed Abdel-Wahab, Alexandre Siciliano Colafranceschi, Lisa Crusius, Fabian Nietlispach, Oliver Husser, Susheel Kodali, Thomas Pilgrim, Stefan Stortecky, Ander Regueiro, David Holzhey, Julio Andrea, Raj Makkar, Nikolaj Ihlemann, Valter Correa Lima, and Henrique Barbosa Ribeiro

Subjects
Male, medicine.medical_specialty, Transcatheter aortic, medicine.medical_treatment, Treatment outcome, MEDLINE, heart valve diseases, Postoperative Complications, Valve replacement, Physiology (medical), medicine, Long term outcomes, Humans, Endocarditis, Hospital Mortality, Registries, 610 Medicine & health, Aged, business.industry, Endocarditis, Bacterial, Middle Aged, medicine.disease, Surgery, Infective endocarditis, endocarditis, transcatheter aortic valve replacement, treatment outcome, Female, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies
Published
2020
Full Text
View/download PDF

7. Infective Endocarditis Following Transcatheter Aortic Valve Replacement

Author

David Messika-Zeitoun, Marcos Antonio Marino, Vincent Auffret, Nikolaj Ihlemann, Hasan Jilaihawi, Mohamed Abdel-Wahab, Oliver Husser, Thomas Walther, Alec Vahanian, Harindra C. Wijeysundera, Luis Nombela-Franco, Raj Makkar, Lars Søndergaard, Marina Urena, John G. Webb, Axel Linke, Ugolino Livi, Costanza Pellegrini, Josep Rodés-Cabau, Luis A. Carvalho, Henrique Barbosa Ribeiro, Francesco Rosato, Antonio J. Muñoz-García, Alberto San Roman, Norman Mangner, Claudia Fiorina, Enrique Gutiérrez-Ibañes, Stefan Stortecky, Hervé Le Breton, Asim N. Cheema, Jan Malte Sinning, Samir R. Kapadia, Azeem Latib, Fabian Nietlispach, Eric Durand, Marco Barbanti, Hélène Eltchaninoff, Antonio L. Bartorelli, Won-Keun Kim, José Armando Mangione, Antonio Miceli, Howard C. Herrmann, John Lisko, Maria Cristina Ferreira, Juan C. Castillo, Dominique Himbert, Alexandre Abizaid, Susheel Kodali, Rishi Puri, Luca Testa, Ignacio J. Amat-Santos, Martin B. Leon, Vicenç Serra, Guglielmo Mario Actis Dato, Jean Bernard Masson, Valter C. Lima, Ander Regueiro, Pedro A. Lemos, Vinicius Esteves, Julio Andrea, Stamatios Lerakis, Fabio Sandoli de Brito, Thomas Pilgrim, and Didier Tchetche

Subjects
Balloon Valvuloplasty, Male, Reoperation, medicine.medical_specialty, Prosthesis-Related Infections, Time Factors, Transcatheter aortic, medicine.medical_treatment, Clinical Decision-Making, registry, Prosthesis Design, Balloon, Risk Assessment, Transcatheter Aortic Valve Replacement, Valve replacement, Aortic valve replacement, Risk Factors, 80 and over, medicine, Humans, Endocarditis, Registries, Device Removal, Aged, Retrospective Studies, endocarditis, incidence, transcatheter aortic valve replacement, Aged, 80 and over, Aortic Valve, Aortic Valve Stenosis, Endocarditis, Bacterial, Female, Incidence, Patient Selection, Treatment Outcome, Heart Valve Prosthesis, Self expandable, business.industry, Bacterial, medicine.disease, Surgery, Infective endocarditis, Cardiology and Cardiovascular Medicine, business
Abstract

Background: No data exist about the characteristics of infective endocarditis (IE) post-transcatheter aortic valve replacement (TAVR) according to transcatheter valve type. We aimed to determine the incidence, clinical characteristics, and outcomes of patients with IE post-TAVR treated with balloon-expandable valve (BEV) versus self-expanding valve (SEV) systems. Methods: Data from the multicenter Infectious Endocarditis After TAVR International Registry was used to compare IE patients with BEV versus SEV. Results: A total of 245 patients with IE post-TAVR were included (SEV, 47%; BEV, 53%). The timing between TAVR and IE was similar between groups (SEV, 5.5 [1.2–15] months versus BEV, 5.3 [1.7–11.4] months; P =0.89). Enterococcal IE was more frequent in the SEV group (36.5% versus 15.4%; P P =0.01; valve leaflet, SEV, 23.9%; BEV, 38.5%; P =0.01). BEV recipients had a higher rate of stroke/systemic embolism (20.0% versus 8.7%, adjusted OR: 2.46, 95% CI: 1.04–5.82, P =0.04). Surgical explant of the transcatheter valve (SEV, 8.7%; BEV, 13.8%; P =0.21), and in-hospital death at the time of IE episode (SEV, 35.6%; BEV, 37.7%; P =0.74) were similar between groups. After a mean follow-up of 13±12 months, 59.1% and 54.6% of the SEV and BEV recipients, respectively, had died ( P =0.66). Conclusions: The characteristics of IE post-TAVR, including microorganism type, vegetation location, and embolic complications but not early or late mortality, differed according to valve type. These results may help to guide the diagnosis and management of IE and inform future research studies in the field.

Published
2019
Full Text
View/download PDF

8. Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death

Author

Marina Urena, Hervé Le Breton, Ugolino Livi, Susheel Kodali, Alec Vahanian, Maria Cristina Ferreira, Francesco Giannini, Luca Testa, Dominique Himbert, Alexandre Abizaid, Asim N. Cheema, Josep Rodés-Cabau, Juan C. Castillo, Francesco Rosato, Vicenç Serra, Vinicius Esteves, Won-Keun Kim, Fabio Sandoli de Brito, Guglielmo Mario Actis Dato, Henrique Barbosa Ribeiro, Vincent Auffret, Azeem Latib, Thomas Pilgrim, Julio Andrea, José Armando Mangione, Marco Barbanti, Marcos Antonio Marino, Alberto San Roman, Oliver Husser, Luis Nombela-Franco, Rishi Puri, Harindra C. Wijeysundera, Didier Tchetche, John G. Webb, Claudia Fiorina, Luiz A. Carvalho, Hélène Eltchaninoff, Nikolaj Ihlemann, Valter Correa Lima, Howard C. Herrmann, John Lisko, Axel Linke, Ander Regueiro, Pedro A. Lemos, Jean Bernard Masson, Mohamed Abdel-Wahab, Lars Søndergaard, David Messika-Zeitoun, Enrique Gutiérrez-Ibañes, Stamatios Lerakis, Costanza Pellegrini, Raj Makkar, Jan Malte Sinning, Antonio J. Muñoz-García, Norman Mangner, Eric Durand, Antonio L. Bartorelli, Antonio Miceli, Stefan Stortecky, Ignacio J. Amat-Santos, Martin B. Leon, Samir R. Kapadia, Thomas Walther, Hasan Jilaihawi, Fabian Nietlispach, Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Université Laval, Service de cardiologie et maladies vasculaires, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Service de cardiologie [CHU Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Nouvelles Cibles Pharmacologiques de la Protection Endothéliale et de l'Insuffisance Cardiaque (EnVI), CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie, Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC-IT Rennes, Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Fundacion Alfonso Martin Escudero, Madrid, Spain, Université Laval [Québec] (ULaval), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, medicine.medical_treatment, 2-year outcomes, 030204 cardiovascular system & hematology, 0302 clinical medicine, Valve replacement, Risk Factors, Interquartile range, Odds Ratio, implantation, Hospital Mortality, Registries, 030212 general & internal medicine, multicenter registry, Endocarditis, Medicine (all), Incidence (epidemiology), Mortality rate, Hazard ratio, Age Factors, Bacterial, regurgitation, Aged, Endocarditis, Bacterial, Female, Follow-Up Studies, Heart Failure, Humans, Sex Factors, Staphylococcal Infections, Staphylococcus aureus, Transcatheter Aortic Valve Replacement, Treatment Outcome, General Medicine, 3. Good health, Infective endocarditis, impact, [SDV.IB]Life Sciences [q-bio]/Bioengineering, metaanalysis, medicine.medical_specialty, prevalence, 03 medical and health sciences, early surgery, medicine, business.industry, Odds ratio, medicine.disease, Surgery, predictors, business
Abstract

International audience; IMPORTANCE Limited data exist on clinical characteristics and outcomes of patients who had infective endocarditis after undergoing transcatheter aortic valve replacement (TAVR). OBJECTIVE To determine the associated factors, clinical characteristics, and outcomes of patients who had infective endocarditis after TAVR. DESIGN, SETTING, AND PARTICIPANTS The Infectious Endocarditis after TAVR International Registry included patients with definite infective endocarditis after TAVR from 47 centers from Europe, North America, and South America between June 2005 and October 2015. EXPOSURE Transcatheter aortic valve replacement for incidence of infective endocarditis and infective endocarditis for in-hospital mortality. MAIN OUTCOMES AND MEASURES Infective endocarditis and in-hospital mortality after infective endocarditis. RESULTS A total of 250 cases of infective endocarditis occurred in 20 006 patients after TAVR (incidence, 1.1% per person-year; 95% Cl, 1.1%44%; median age, 80 years; 64% men). Median time from TAVR to infective endocarditis was 5.3 months (interquartile range [IQR], 1.5-13.4 months). The characteristics associated with higher risk of progressing to infective endocarditis after TAVR was younger age (78.9 years vs 81.8 years; hazard ratio [HR], 0.97 per year; 95% CI, 0.94-0.99), male sex (62.0% vs 49.7%; HR, 1.69; 95% C1,1.13-2.52), diabetes mellitus (41.7% vs 30.0%; HR, 1.52; 95% Cl, 1.02-2.29), and moderate to severe aortic regurgitation (22.4% vs 14.7%; HR, 2.05; 95% Cl, 1.28-3.28). Health care-associated infective endocarditis was present in 52.8% (95% Cl, 46.6%-59.0%) of patients. Enterococci species and Staphylococcus aureus were the most frequently isolated microorganisms (24.6%; 95% Cl, 19.1%-30.1% and 23.3%; 95% Cl, 17.9%-28.7%, respectively). The in-hospital mortality rate was 36% (95% Cl, 30.0%-41.9%; 90 deaths; 160 survivors), and surgery was performed in 14.8% (95% Cl, 10.4%-19.2%) of patients during the infective endocarditis episode. In-hospital mortality was associated with a higher logistic EuroSCORE (23.1% vs 18.6%; odds ratio [OR], 1.03 per 1% increase; 95% C1,1.00-1.05), heart failure (59.3% vs 23.7%; OR, 3.36; 95% Cl, 1.74-6.45), and acute kidney injury (67.4% vs 31.6%; OR, 2.70; 95% C1,1.42-5.11). The 2-year mortality rate was 66.7% (95% Cl, 59.0%-74.2%; 132 deaths; 115 survivors). CONCLUSIONS AND RELEVANCE Among patients undergoing TAVR, younger age, male sex, history of diabetes mellitus, and moderate to severe residual aortic regurgitation were significantly associated with an increased risk of infective endocarditis. Patients who developed endocarditis had high rates of in-hospital mortality and 2-year mortality.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results